Before treatment, his CGM showed: frequent glucose spikes after meals a persistently elevated baseline glucose , even between meals and overnight This pattern suggests prolonged glucose exposure and repeated insulin demand throughout the day
Meanwhile, Eli Lilly, which manufactures Zepbound, is navigating a growing number of legal complaints that accuse the company of not telling people about some of the potential gastrointestinal risks of taking Zepbound
Breast cancer is the most common cancer among women in the U.S., making up more than 30% of all cases
Wegovy is not recommended during breastfeeding because there is insufficient clinical data on whether semaglutide passes into human breast milk or what effects it might have on nursing infants
GHK-Cu requires daily subcutaneous injection, which is a meaningful compliance requirement
Today's oral GLP-1s give 13-15% weight loss at 36 weeks (orforglipron Phase 2)